New Zealand markets open in 1 hour 18 minutes

Histogen Inc. (HSTO)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.3150-0.0050 (-1.56%)
At close: 03:27PM EST

Histogen Inc.

10655 Sorrento Valley Road
Suite 200
San Diego, CA 92121
United States
858 526 3100

Full-time employees7

Key executives

NameTitlePayExercisedYear born
Ms. Susan A. KnudsonPresident, CEO, CFO, COO, Chief Compliance Officer & Corporate Secretary653.2kN/A1964
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California.

Corporate governance

Histogen Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.